Amgen Neupogen
Executive Summary
PLA filing for the white blood cell growth factor was completed on Dec. 28. Amgen is seeking to market Neupogen (G-CSF, or granulocyte colony stimulating factor) as an adjunct to chemotherapy in certain cancers, primarily small cell lung cancer. The PLA includes data on more than 700 cancer patients from eight clinical centers in the U.S. and Europe.